Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GKOS

GKOS - Glaukos Corp Stock Price, Fair Value and News

$123.96+5.26 (+4.43%)
Market Closed

23/100

GKOS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

GKOS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$95.98

Target 3M

$107.98

Target 6M

$101.98

GKOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GKOS Price Action

Last 7 days

-0.2%

Last 30 days

7.3%

Last 90 days

41.2%

Trailing 12 Months

-22.4%

GKOS RSI Chart

GKOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GKOS Valuation

Market Cap

7.1B

Price/Earnings (Trailing)

-81.26

Price/Sales (Trailing)

15.15

EV/EBITDA

-97.84

Price/Free Cashflow

-258.03

GKOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$95.98

Target 3M

$107.98

Target 6M

$101.98

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

469.8M

Rev. Growth (Yr)

38.14%

Rev. Growth (Qtr)

7.59%

GKOS Earnings

Earnings (TTM)

-87.6M

Earnings Growth (Yr)

24.19%

Earnings Growth (Qtr)

17.43%

GKOS Profitability

EBT Margin

-18.50%

Return on Equity

-11.39%

Return on Assets

-8.77%

Free Cashflow Yield

-0.39%

GKOS Investor Care

Shares Dilution (1Y)

4.17%

Diluted EPS (TTM)

-1.51

GKOS Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025404.5M433.0M469.8M0
2024326.4M341.7M360.3M383.5M
2023289.1M296.8M303.6M314.7M
2022293.7M288.3M284.9M282.9M
2021237.6M284.1M294.0M294.0M
2020238.3M211.3M217.6M225.0M
2019195.2M210.6M225.2M237.0M
2018163.5M165.4M168.9M181.3M
2017127.2M139.9M150.8M159.3M
201680.1M90.9M101.5M114.4M
201552.0M58.7M65.5M71.7M
201427.1M33.3M39.4M45.6M
201300020.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Glaukos Corp

GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
 CEO
 WEBSITEglaukos.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES783

Glaukos Corp Frequently Asked Questions

GKOS is the stock ticker symbol of Glaukos Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Glaukos Corp is 7.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GKOS's fair value in chart for subscribers.

The fair value guage provides a quick view whether GKOS is over valued or under valued. Whether Glaukos Corp is cheap or expensive depends on the assumptions which impact Glaukos Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GKOS.

As of Wed Jan 28 2026, GKOS's PE ratio (Price to Earnings) is -81.26 and Price to Sales (PS) ratio is 15.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GKOS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Glaukos Corp has provided 0.225 (multiply by 100 for percentage) rate of return.